Aleix Prat

37.0k citations

404 papers · 15.0k · 5 hit papers · h-index 55

Impact in

Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways

Papers in

Oncology 262
- HER2/EGFR in Cancer Research 134
- Cancer Treatment and Pharmacology 64
- Cancer Immunotherapy and Biomarkers 51
- Cancer Cells and Metastasis 19
Pulmonary and Respiratory Medicine 183
- Advanced Breast Cancer Therapies 145

Co-authors: Charles M. Perou (62 shared papers)Joel S. Parker (26 shared papers)Cheng Fan (12 shared papers)Bárbara Adamo (47 shared papers)Xiaping He (6 shared papers)Olga Karginova (8 shared papers)Chad Livasy (3 shared papers)Jason I. Herschkowitz (3 shared papers)
Journals: Annals of Oncology (75 papers)Cancer Research (65 papers)Journal of Clinical Oncology (63 papers)ESMO Open (22 papers)Clinical Cancer Research (14 papers)
Partner nations: Spain United States Italy

In The Last Decade

Aleix Prat

376 papers receiving 14.8k citations

Aleix Prat's Hit Papers

5 papers align trajectories log scale

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study 2021 · 232 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet Oncology
2020 Nature Reviews Disease Primers
2015 The Breast
2010 Breast Cancer Research
2010 Molecular Oncology

Peers

Countries citing papers authored by Aleix Prat

Since Specialization

Citations

This map shows the geographic impact of Aleix Prat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleix Prat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleix Prat more than expected).

Fields of papers citing papers by Aleix Prat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleix Prat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleix Prat. The network helps show where Aleix Prat may publish in the future.

Co-authors

The 25 scholars most cited alongside Aleix Prat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aleix Prat Line = papers co-authored together Aleix Prat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 404 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Research ·Aleix Prat, Joel S. Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I. Herschkowitz, Xiaping He, Charles M. Perou Hit paper breakdown →	2010	1581
2	Immune-related adverse events of checkpoint inhibitors Nature Reviews Disease Primers ·Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh M. Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, María E. Suarez‐Almazor Hit paper breakdown →	2020	985
3	Deconstructing the molecular portraits of breast cancer Molecular Oncology ·Aleix Prat, Charles M. Perou Hit paper breakdown →	2010	960
4	Clinical implications of the intrinsic molecular subtypes of breast cancer The Breast ·Aleix Prat, Estela Pineda, Bárbara Adamo, Patricia Galván, Aranzazu Fernández-Martínez, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz-Mateu Hit paper breakdown →	2015	778
5	Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer Journal of Clinical Oncology ·Aleix Prat, Maggie C.U. Cheang, Miguel Martín, Joel S. Parker, Eva Carrasco, Rosalía Caballero, Scott Tyldesley, Karen A. Gelmon, Philip S. Bernard, Torsten O. Nielsen, Charles M. Perou	2012	425
6	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer The Oncologist ·Aleix Prat, Bárbara Adamo, Maggie C.U. Cheang, Carey K. Anders, Lisa A. Carey, Charles M. Perou	2013	407
7	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 Journal of Clinical Oncology ·Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson	2011	377
8	USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma Nature Medicine ·Pieter J.A. Eichhorn, Laura Rodón, Alba Gonzàlez-Juncà, Annette M.G. Dirac, Magüi Gili, Elena Martínez‐Sáez, Claudia Aura, Ignasi Barba, Vicente Peg, Aleix Prat, Isabel Cuartas, José Jimenez, David García‐Dorado, Juan Sahuquillo, René Bernards, José Baselga, Joan Seoane	2012	335
9	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Annals of Oncology ·Rodrigo Dienstmann, Jordi Rodón, Aleix Prat, José Manuel Pérez-García, Bárbara Adamo, Enriqueta Felip, Javier Cortés, A. John Iafrate, Paolo Nucíforo, Josep Tabernero	2013	304
10	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma Cancer Research ·Aleix Prat, Alejandro Navarro, Laia Paré, Noemı́ Reguart, Patricia Galván, Tomás Pascual, Alex Martínez‐Martí, Paolo Nucíforo, Laura Comerma, Llúcia Alós, Núria Pardo, S. Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Núria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip	2017	283
11	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients Proceedings of the National Academy of Sciences ·Maurizio Scaltriti, Pieter J.A. Eichhorn, Javier Cortés, Ludmila Prudkin, Claudia Aura, José Jimenez, Sarat Chandarlapaty, Violeta Serra, Aleix Prat, Yasir H. Ibrahim, Marta Guzmán, Magüi Gili, Olga Rodríguez, Sónia Rodríguez, José Pérez, Simon R. Green, Sabine Mai, Neal Rosen, Clifford A. Hudis, José Baselga	2011	259
12	Frequency and spectrum of PIK3CA somatic mutations in breast cancer Breast Cancer Research ·Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Bárbara Adamo, María Vidal, Blanca González‐Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, (unknown), Patricia Galván, Ana Rodríguez, Antonio Martı́nez, Montserrat Muñoz-Mateu, Aleix Prat	2020	243
13	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study The Lancet Oncology ·Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia Hit paper breakdown →	2021	232
14	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer Bioinformatics ·Deena M.A. Gendoo, Natchar Ratanasirigulchai, Markus Schröder, Laia Paré, Joel S. Parker, Aleix Prat, Benjamin Haibe‐Kains	2015	227
15	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial The Lancet Oncology ·Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, Patricia Galván, Begoña Bermejo, Noelia Martínez-Jáñez, María Vidal, Sònia Pernas, Rafael López‐López, Montserrat Muñoz-Mateu, Paolo Nucíforo, Serafín Morales, Mafalda Oliveira, Lorena de la Peña, Alexandra Peláez, Aleix Prat	2017	217
16	Practical implications of gene-expression-based assays for breast oncologists Nature Reviews Clinical Oncology ·Aleix Prat, Matthew J. Ellis, Charles M. Perou	2011	212
17	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 Nature Communications ·Jessica Bockhorn, Rachel Dalton, Chika Nwachukwu, Simo Huang, Aleix Prat, Kathy Yee, Ya-Fang Chang, Dezheng Huo, Yujia Wen, Kaitlin E. Swanson, Tyler Qiu, Jun Lü, Seo Young Park, M. Eileen Dolan, Charles M. Perou, Olufunmilayo I. Olopade, Michael F. Clarke, Geoffrey L. Greene, Huiping Liu	2013	203
18	How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More? JNCI Journal of the National Cancer Institute ·William F. Anderson, Philip S. Rosenberg, Aleix Prat, Charles M. Perou, Mark E. Sherman	2014	197
19	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models Journal of Clinical Investigation ·X. Cynthia, Shirong Cai, Shunqiang Li, Christine E. Ryan, Zhanfang Guo, W. Timothy Schaiff, Lin Li, Jeremy Hoog, Reece Goiffon, Aleix Prat, Rebecca Aft, Matthew J. Ellis, Helen Piwnica‐Worms	2012	168
20	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse Breast Cancer Research and Treatment ·J. Chuck Harrell, Aleix Prat, Joel S. Parker, (unknown), Xiaping He, Lisa A. Carey, Carey K. Anders, Matthew G. Ewend, Charles M. Perou	2011	167

About Aleix Prat

Aleix Prat is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 404 papers that have together received 15.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (145 papers), HER2/EGFR in Cancer Research (134 papers), Breast Cancer Treatment Studies (129 papers), Cancer Treatment and Pharmacology (64 papers), Cancer Immunotherapy and Biomarkers (51 papers), Cancer Genomics and Diagnostics (39 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Cancer Cells and Metastasis (19 papers). The work is most often cited by research in Cancer Research (4.9k citations), Oncology (7.1k citations), Pulmonary and Respiratory Medicine (2.7k citations), Molecular Biology (5.0k citations) and Immunology (1.1k citations). Aleix Prat has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Charles M. Perou, Joel S. Parker, Cheng Fan, Bárbara Adamo, Xiaping He, Olga Karginova, Chad Livasy, Jason I. Herschkowitz, Patricia Galván and Lisa A. Carey. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, ESMO Open and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Aleix Prat

Impact in

Papers in i

In The Last Decade

Aleix Prat

Aleix Prat's Hit Papers

Peers

Countries citing papers authored by Aleix Prat

Fields of papers citing papers by Aleix Prat

All Works

About Aleix Prat

Explore authors with similar magnitude of impact

Papers in